Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis by Jaguszewski, Milosz J. et al.
Address for correspondence: Aleksandra Gąsecka, MD, PhD, 1st Chair and Department of Cardiology, Medical University  
of Warsaw, ul. Banacha 1a, 02–097 Warszawa, Poland, tel: +48 22 599 19 51, e-mail: aleksandra.gasecka@wum.edu.pl
Received: 26.02.2021 Accepted: 14.03.2021
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Efficacy and safety of levosimendan  
and dobutamine in heart failure:  
A systematic review and meta-analysis
Milosz J. Jaguszewski1 , Aleksandra Gasecka2, 3 , Radoslaw Targonski1, 4,  
Krzysztof J. Filipiak2 , Lukasz Szarpak5, 6
11st Department of Cardiology, Medical University of Gdansk, Poland  
21st Chair and Department of Cardiology, Medical University of Warsaw, Poland 
3Department of Cardiology, University Medical Center Utrecht, The Netherlands 
4Department of Cardiac and Vascular Surgery, Medical University of Gdansk, Poland 
5Maria Sklodowska-Curie Medical Academy in Warsaw, Poland 
6Maria Sklodowska-Curie Białystok Oncology Center, Białystok, Poland
This paper was guest edited by Prof. Togay Evrin
Levosimendan is a new inodilator which has 
three main mechanisms of action: increases the 
calcium sensitivity of cardiomyocytes by binding to 
cardiac troponin C, acts as a vasodilator due to the 
opening of potassium channels, thus exerting cardio-
protective effects [1]. Due to the unique mechanism 
of action, levosimendan has multifaceted cardio-
protective effects, as demonstrated previously [2]. 
Levosimendan is indicated for inotropic support in 
acute decompensated heart failure (HF) in situations 
where conventional therapy is not sufficient, and in 
cases where inotropic support is considered appro-
priate (class IIb recommendation according to the 
European Society of Cardiology guidelines) [3]. In 
addition, levosimendan was showed to accelerate the 
recovery in patients with takotsubo cardiomyopathy 
[4]. Dobutamine, in turn, remains the most widely 
used therapy in patients with acute decompensated 
HF. Although dobutamine improves hemodynamics 
and symptoms in these patients, it has been associ-
ated with an increased risk of death and other cardio-
vascular events [5]. Hence, there is a greatly unmet 
need for agents that improve hemodynamics and 
relieve symptoms without adversely affecting sur-
vival. In contrast to dobutamine, levosimendan has 
a safe and predictable profile of action and does not 
induce tolerance, facilitating its administration in 
HF patients [6]. 
Because the results of previous clinical studies 
are inconclusive, herein was performed a system-
atic review and meta-analysis to verify the efficacy 
and safety of levosimendan and dobutamine in pa-
tients with acute HF. Two authors (L.S. and A.G.) 
independently searched PubMed, the Cochrane 
Library and the Google Scholar for articles writ-
ten in English (last update January 7th, 2021). The 
key search words were: “levosimendan” AND 
“dobutamine” AND “heart failure” OR “HF”. All 
statistical analyses were performed with Review 
Manager Software 5.4 (The Cochrane Collabora-
tion, Oxford, Copenhagen, Denmark). All results 
are presented as mean difference (MD) or odds 
ratio (OR) with 95% confidence interval (CI). When 
the continuous outcome was reported in a study 
as median, range, and interquartile range, means 
and standard deviations were estimated using the 
formula described by Hozo et al. [7]. The random-
effects model was used for I2 > 50%. Statistical 
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Ten studies including 2305 were eligible for 
quantitative analysis. The full list of the included 
publications is presented in Supplementary 
Digital Content. Characteristics of included stud-
ies was presented in Supplementary Table S1. 
In-hospital mortality (or 30-day mortality) group 
was reported in 10 studies and occurred in 8.4% 
patients treated with levosimendan and 12.7% 
patients treated with dobutamine (OR = 0.65; 
95% CI: 0.50–0.86; p = 0.002; I2 = 47%; Fig. 1). 
In contrast, 6-month mortality was reported in 
3 studies and was 25.8% for levosimendan com-
pared with 29.5% for dobutamine (OR = 0.84; 95% 
CI: 0.67–1.04; p = 0.11; I2 = 36%; Suppl. Fig. S1).
The use of levosimendan compared to do-
butamine was associated with a lower frequency 
of complications including acute decompensated 
cardiac failure (12.2% vs. 16.8%, respectively; 
OR = 69; 95% CI: 0.51–0.93; p = 0.02; I2 = 0%), 
and a higher risk of atrial fibrillation (8.1% vs. 5.4%; 
OR = 1.56; 95% CI: 1.04–2.35; p = 0.03; I2 = 0%). 
A detailed overview of adverse events is presented 
in Supplementary Table S2.
Length of hospital stay was 10.7 ± 7.0 days in 
the levosimendan group compared to 12.4 ± 6.6 
days in the dobutamine group (MD = –1.92; 95% 
CI: –2.47 to –1.36; p < 0.001; I2 = 0%; Suppl. 
Fig. S2).
In conclusion, the present study demonstrated 
that levosimendan decreased in-hospital (or 30- 
-days) mortality and length of hospital stay, com-
pared to dobutamine. In addition, there was a trend 
towards lower 6-month mortality on levosimendan. 
Taking into account the promising results of our 
meta-analysis and the cardioprotective effects of 
levosimendan demonstrated in multiple studies, 
there is a need for a well-designed multicenter 
randomized placebo-controlled study, including an 
adequately large group of outpatients with acute 
HF to ultimately determine the effect of levosi-
mendan on long-term prognosis [8]. 
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Figure 1. Forest plot of in-hospital mortality in the levosimendan versus the dobutamine group. The center of each 
square represents the weighted odds ratio for individual trials, and the corresponding horizontal line stands for 95% 
confidence interval (CI). The diamonds represent pooled results. Procedure time presented in seconds.
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